{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:01:40Z","timestamp":1776859300106,"version":"3.51.2"},"reference-count":40,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"Background:<\/jats:bold> Among breast cancer survivors, urinary incontinence (UI) is often attributed to cancer therapy. We prospectively assessed urinary symptoms before and after (neo)adjuvant treatment of early-stage breast cancer. Methods:<\/jats:bold> With consent, women with stage I\u2013III breast cancer completed the Urogenital Distress Inventory and the Incontinence Impact Questionnaire before and 3 months after initiating (neo)adjuvant therapy. Patients with UI were at least slightly bothered by urinary symptoms. If UI was present pretreatment, it was considered prevalent; if UI was new or worse at 3 months posttreatment, it was considered incident; if prevalent UI was no worse at 3 months posttreatment, it was considered stable. Ordinal logistic regression models identified characteristics associated with the level of prevalent UI and with the degree of UI impact on quality of life (QoL). Results:<\/jats:bold> On pretreatment surveys, participants (N=203; age 54.5 \u00b1 11.4 years) reported 79.8% prevalence of UI, including overactive bladder (29.1%), stress incontinence (10.8%), or both (39.9%). The level of prevalent UI increased with body mass index (BMI; P<\/jats:italic><.05). Of 163 participants assessed at both time points, incident UI developed in 12 of 32 patients without prevalent UI and 27 of 131 patients with prevalent UI. Regardless of whether UI was prevalent (n=162), incident (n=39), or stable (n=94) at QoL assessment, the impact of UI increased (P<\/jats:italic><.01) with the number and severity of UI symptoms, subjective urinary retention, and BMI. Adjusted for those characteristics, incident UI had less impact on QoL (P<\/jats:italic><.05) than did prevalent or stable UI. Conclusions:<\/jats:bold> We found that UI is highly prevalent at breast cancer diagnosis and that new or worsened UI is common after (neo)adjuvant therapy. Because UI often impairs QoL, appropriate treatment strategies are needed.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7535","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:31:47Z","timestamp":1591385507000},"page":"712-716","source":"Crossref","is-referenced-by-count":15,"title":["Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy"],"prefix":"10.6004","volume":"18","author":[{"given":"Christopher P.","family":"Chung","sequence":"first","affiliation":[{"name":"1Urogynecology, Division of Gynecologic Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Behrendt","sequence":"additional","affiliation":[{"name":"2Division of Biostatistics, Department of Computational and Quantitative Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Wong","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, City of Hope National Medical Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Flores","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, City of Hope National Medical Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Mortimer","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, City of Hope National Medical Center, Duarte, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"ref61","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","article-title":"Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Land","year":"2006","journal-title":"JAMA"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.juro.2006.09.045","article-title":"Care seeking and treatment for urinary incontinence in a diverse population","volume":"177","author":"Harris","year":"2007","journal-title":"J Urol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.juro.2011.03.114","article-title":"Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008","volume":"186","author":"Markland","year":"2011","journal-title":"J Urol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"M67","DOI":"10.1093\/geronj\/45.2.M67","article-title":"Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults","volume":"45","author":"Herzog","year":"1990","journal-title":"J Gerontol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/bjc.2012.43","article-title":"Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation","volume":"106","author":"Fallowfield","year":"2012","journal-title":"Br J Cancer"},{"key":"ref191","article-title":"Guidelines in Version Accessed To view the most recent version visitNCCN org","volume":"16","author":"SanftT","year":"2019","journal-title":"Clinical Practice Oncology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10549-007-9682-9","article-title":"Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women","volume":"109","author":"Cella","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"Quality of life of postmenopausal women in the ATAC (\u201cArimidex,\u201d tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for early breast cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00280-013-2227-5","article-title":"Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study","volume":"72","author":"Yoo","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2015.64.3866","article-title":"Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the Mind-Body Study","volume":"34","author":"Ganz","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/bjc.2012.43","article-title":"Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation","volume":"106","author":"Fallowfield","year":"2012","journal-title":"Br J Cancer"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.juro.2006.09.045","article-title":"Care seeking and treatment for urinary incontinence in a diverse population","volume":"177","author":"Harris","year":"2007","journal-title":"J Urol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","article-title":"Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Ganz","year":"2016","journal-title":"Lancet"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/nau.1930140206","article-title":"Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory","volume":"14","author":"Uebersax","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2015.64.3866","article-title":"Impact of adjuvant endocrine therapy on quality of life and symptoms: observational data over 12 months from the Mind-Body Study","volume":"34","author":"Ganz","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/nau.22235","article-title":"Predictors of care seeking in women with urinary incontinence","volume":"31","author":"Minassian","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jnci\/dji069","article-title":"The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer","volume":"97","author":"Stanton","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00280-013-2227-5","article-title":"Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study","volume":"72","author":"Yoo","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/jama.300.11.1311","article-title":"Prevalence of symptomatic pelvic floor disorders in US women","volume":"300","author":"Nygaard","year":"2008","journal-title":"JAMA"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/GME.0000000000000926","article-title":"Missing documentation in breast cancer survivors: genitourinary syndrome of menopause","volume":"24","author":"Cook","year":"2017","journal-title":"Menopause"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","article-title":"Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Land","year":"2006","journal-title":"JAMA"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"Quality of life of postmenopausal women in the ATAC (\u201cArimidex,\u201d tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for early breast cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/nau.22235","article-title":"Predictors of care seeking in women with urinary incontinence","volume":"31","author":"Minassian","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jnci\/dji069","article-title":"The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer","volume":"97","author":"Stanton","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref01","article-title":"Facts Figures Accessed Available at http www cancer org content dam cancer org research cancer facts and statistics annual cancer facts and figures cancer facts and figures pdf","volume":"16","author":"January","year":"2017","journal-title":"American Cancer Society Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/92.13.1054","article-title":"Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial","volume":"92","author":"Ganz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"M67","DOI":"10.1093\/geronj\/45.2.M67","article-title":"Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults","volume":"45","author":"Herzog","year":"1990","journal-title":"J Gerontol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/GME.0000000000000943","article-title":"Factors associated with reasons incontinent midlife women report for not seeking urinary incontinence treatment over 9 years across the menopausal transition","volume":"25","author":"Waetjen","year":"2018","journal-title":"Menopause"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/92.13.1054","article-title":"Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial","volume":"92","author":"Ganz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","article-title":"Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Ganz","year":"2016","journal-title":"Lancet"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/jama.300.11.1311","article-title":"Prevalence of symptomatic pelvic floor disorders in US women","volume":"300","author":"Nygaard","year":"2008","journal-title":"JAMA"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/GME.0000000000000943","article-title":"Factors associated with reasons incontinent midlife women report for not seeking urinary incontinence treatment over 9 years across the menopausal transition","volume":"25","author":"Waetjen","year":"2018","journal-title":"Menopause"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/GME.0000000000000926","article-title":"Missing documentation in breast cancer survivors: genitourinary syndrome of menopause","volume":"24","author":"Cook","year":"2017","journal-title":"Menopause"},{"key":"ref391","article-title":"Guidelines in Version Accessed To view the most recent version visitNCCN org","volume":"16","author":"SanftT","year":"2019","journal-title":"Clinical Practice Oncology"},{"key":"ref201","article-title":"Facts Figures Accessed Available at http www cancer org content dam cancer org research cancer facts and statistics annual cancer facts and figures cancer facts and figures pdf","volume":"16","author":"January","year":"2017","journal-title":"American Cancer Society Cancer"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10549-007-9682-9","article-title":"Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women","volume":"109","author":"Cella","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.juro.2011.03.114","article-title":"Prevalence and trends of urinary incontinence in adults in the United States, 2001 to 2008","volume":"186","author":"Markland","year":"2011","journal-title":"J Urol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/nau.1930140206","article-title":"Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory","volume":"14","author":"Uebersax","year":"1995","journal-title":"Neurourol Urodyn"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p712.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/6\/article-p712.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T18:48:27Z","timestamp":1592592507000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p712.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":40,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7535","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}